Please use this identifier to cite or link to this item: http://hdl.handle.net/2445/205415
Title: Side Effects from Cancer Therapies and Perspective of 1044 Long-Term Ovarian Cancer Survivors—Results of Expression VI–Carolin Meets HANNA–Holistic Analysis of Long-Term Survival with Ovarian Cancer: The International NOGGO, ENGOT, and GCIG Survey
Author: Woopen, Hannah
Keller, Maren
Zocholl, Dario
Mittelstadt, Suzana
Barretina Ginesta, Maria Pilar
Heinzelmann-Schwarz, Viola
Lafleur, Judith
Kocián, Roman
Baum, Joanna
Krabisch, Petra
Achimas Cadariu, Patriciu
Vardar, Mehmet Ali
Vergote, Ignace
Nasser, Sara
Link, Theresa
Gil Martín, Marta
Zwimpfer, Tibor A.
Leitner, Katharina
Jedryka, Marcin
Boxler, Tamara
Braicu, Elena Ioana
Sehouli, Jalid
Keywords: Càncer d'ovari
Efectes secundaris
Ovarian cancer
Side effects
Issue Date: 15-Nov-2023
Publisher: MDPI AG
Abstract: The aim of this survey was to increase the knowledge on the characteristics and health concerns of long-term survivors (LTS; survival > 5 years) after ovarian cancer in order to tailor follow-up care. This international survey was initiated by the NOGGO and was made available to members of ENGOT and GCIG. The survey is anonymous and consists of 68 questions regarding sociodemographic, medical (cancer) history, health concerns including distress, long-term side effects, and lifestyle. For this analysis, 1044 LTS from 14 countries were recruited. In total, 58% were diagnosed with FIGO stage III/IV ovarian cancer and 43.4% developed recurrent disease, while 26.0% were receiving cancer treatment at the time of filling in the survey. LTS who survived 5-10 years self-estimated their health status as being significantly worse than LTS who survived more than 10 years (p = 0.034), whereas distress also remained high 10 years after cancer diagnosis. Almost half of the cohort (46.1%) reported still having symptoms, which were mainly lymphedema (37.7%), fatigue (23.9%), pain (21.6%), polyneuropathy (16.9%), gastrointestinal problems (16.6%), and memory problems (15.5%). Almost all patients (94.2%) regularly received follow-up care. Specialized survivorship care with a focus on long-term side effects, lifestyle, and prevention should be offered beyond the typical five years of follow-up care.
Note: Reproducció del document publicat a: https://doi.org/10.3390/cancers15225428
It is part of: Cancers, 2023, vol. 15, num. 22
URI: http://hdl.handle.net/2445/205415
Related resource: https://doi.org/10.3390/cancers15225428
ISSN: 2072-6694
Appears in Collections:Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))

Files in This Item:
File Description SizeFormat 
cancers-15-05428.pdf948.01 kBAdobe PDFView/Open


This item is licensed under a Creative Commons License Creative Commons